Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

BACKGROUND: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor, for the treatment of patients admitted to hospital with COVID-19. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multipl...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333998/
https://www.ncbi.nlm.nih.gov/pubmed/35908569
http://dx.doi.org/10.1016/S0140-6736(22)01109-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333998/
https://www.ncbi.nlm.nih.gov/pubmed/35908569
http://dx.doi.org/10.1016/S0140-6736(22)01109-6

Ejemplares similares